{"created":"2023-07-27T06:51:50.805571+00:00","id":45429,"links":{},"metadata":{"_buckets":{"deposit":"afbd1554-2e15-4b02-826a-fb2cf71da985"},"_deposit":{"created_by":18,"id":"45429","owners":[18],"pid":{"revision_id":0,"type":"depid","value":"45429"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00045429","sets":["2812:2813:2820"]},"author_link":["78939","2269"],"item_9_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2014-06-12","bibliographicIssueDateType":"Issued"},"bibliographicPageStart":"5p.","bibliographicVolumeNumber":"2012-04-01 - 2014-03-31","bibliographic_titles":[{"bibliographic_title":"平成25(2013)年度 科学研究費補助金 若手研究(B) 研究成果報告書"},{"bibliographic_title":"2013 Fiscal Year Final Research Report","bibliographic_titleLang":"en"}]}]},"item_9_creator_33":{"attribute_name":"著者別表示","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{}],"nameIdentifiers":[{},{}]}]},"item_9_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"我々は悪性神経膠種における、セリン・スレオニンキナーゼファミリーであるglycogen synthase kinase 3β (GSK3β) の関与に着目し、GSKβを阻害することで、膠芽腫細胞の増殖・浸潤が抑制され、現在臨床で使用されている抗がん剤の効果を相乗的に増加させるという基礎研究結果をすでに得ている。マウス腫瘍モデルを用いた検討では、生体内でもGSK3β阻害による腫瘍増殖抑制効果を確認、その分子生物学的メカニズムの解明も進めており、C-Mycという分子が関与していることを報告した。また、GSK3β阻害作用をもつ既存の薬剤を使用した、再発膠芽腫に対する第I/II相臨床試験を行っている。","subitem_description_type":"Abstract"},{"subitem_description":"We focus on the glycogen synthase kinase 3beta,serine-threonine kinase family, demonstrated that inhibition of GSK3beta supresses proliferation and invasion of glioblastoma cells ,and increases the effect of anti-cancer drugs synergistically. In the study using a mouse tumor model, we demonstrated tumor growth inhibitory effect of GSK3be-ta inhibition in vivo. We reported that GSK3be-ta inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling. In addition, using existing drugs with GSK3be-ta inhibitory effect, we conducted clinical trial for recurrent glioblastoma.","subitem_description_type":"Abstract"}]},"item_9_description_22":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"研究課題/領域番号:24791491, 研究期間(年度):2012-04-01 - 2014-03-31","subitem_description_type":"Other"},{"subitem_description":"出典：研究課題「GSK3βを分子標的とする悪性グリオーマ治療の基礎基盤の構築」課題番号24791491\n（KAKEN：科学研究費助成事業データベース（国立情報学研究所））\n（https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-24791491/24791491seika/）を加工して作成","subitem_description_type":"Other"}]},"item_9_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.24517/00051766","subitem_identifier_reg_type":"JaLC"}]},"item_9_publisher_17":{"attribute_name":"公開者","attribute_value_mlt":[{"subitem_publisher":"金沢大学附属病院脳神経外科"}]},"item_9_relation_28":{"attribute_name":"関連URI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/search/?qm=80624874"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/search/?qm=80624874","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-24791491/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-24791491/","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-24791491/24791491seika/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-24791491/24791491seika/","subitem_relation_type_select":"URI"}}]},"item_9_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-07-23"}],"displaytype":"detail","filename":"ME-PR-MIYASHITA-K-kaken 2014-5p.pdf","filesize":[{"value":"258.3 kB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"ME-PR-MIYASHITA-K-kaken 2014-5p.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/45429/files/ME-PR-MIYASHITA-K-kaken 2014-5p.pdf"},"version_id":"741a1372-2774-4729-8ace-ac8fa58308a9"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"research report","resourceuri":"http://purl.org/coar/resource_type/c_18ws"}]},"item_title":"GSK3βを分子標的とする悪性グリオーマ治療の基礎基盤の構築","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"GSK3βを分子標的とする悪性グリオーマ治療の基礎基盤の構築"},{"subitem_title":"Basic base constraction of malignant glioma therapy targeting for GSK3beta","subitem_title_language":"en"}]},"item_type_id":"9","owner":"18","path":["2820"],"pubdate":{"attribute_name":"公開日","attribute_value":"2018-07-23"},"publish_date":"2018-07-23","publish_status":"0","recid":"45429","relation_version_is_last":true,"title":["GSK3βを分子標的とする悪性グリオーマ治療の基礎基盤の構築"],"weko_creator_id":"18","weko_shared_id":-1},"updated":"2023-07-27T09:18:17.395648+00:00"}